PR Newswire · Press release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medline Inc. - MDLN
AI summary
Summary by Wenlo · not part of the original release
On October 29, 2026, Pomerantz LLP announced an investigation into Medline Inc. on behalf of investors. The inquiry follows an FDA warning letter on June 2, 2026, regarding manufacturing violations, which caused the stock to fall $2.56 per share, or 7.16%, to close at $33.19. Medline later acknowledged on August 5, 2026, that remediation steps resulted in earnings loss, sending the stock down another $5.38 per share, or 12.79%, to close at $36.67.
AI summaries can miss details: read the full release below. Not investment advice.
Original release from PR Newswire
As distributed by PR Newswire, unedited.
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Medline and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On June 2, 2026, the U.S. Food and Drug Administration ("FDA") published a warning letter detailing Medline's "significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals" and stating that Medline "failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications."
On this news, Medline's stock price fell $2.56 per share, or 7.16%, to close at $33.19 per share on June 2, 2026.
Then, on August 5, 2026, Medline acknowledged in an earnings call that at least some of the remediation steps taken to address the issues in the FDA's warning letter had "result[ed] in earnings loss".
On this news, Medline's stock price fell $5.38 per share, or 12.79%, to close at $36.67 per share on August 5, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980
View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-medline-inc---mdln-302923453.html
SOURCE Pomerantz LLP
